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Résumé 
Plusieurs articles scientifiques et manuels de référence en médecine 
comportementale distinguent l'hyperactivité ou hyperkinésie de l’activité excessive en 
évaluant la réponse physiologique et comportementale des chiens suite à l’administration 
per os de 0.2 à 1.0 mg/kg de dextroamphétamine.  Selon ces références, le chien atteint 
d’un syndrome hyperactif ou hyperkinésie, répondra de façon paradoxale à cette médication 
par une diminution de l’activité motrice accompagnée d’une réduction minimale de 15% de 
la fréquence respiratoire et de la fréquence cardiaque. L’objectif de la présente étude était 
de mesurer la variation de la température corporelle, de la fréquence cardiaque, de l’activité 
motrice et de différents comportements spécifiques chez un groupe de Beagles ayant reçu 
de la dextroamphétamine. La fiabilité d'un accéléromètre comme mesure objective 
d’activité motrice a aussi été évaluée.  
Dans le cadre de cette étude croisée contrôlée par placebo, douze Beagles de la 
colonie de recherche âgés entre 13 et 20 mois ont reçu une dose orale de 0.2 mg/kg de 
dextroamphétamine.  Le moniteur cardiaque Polar® et un accéléromètre Actical® ont été 
utilisés pour enregistrer la fréquence cardiaque et l’activité motrice avant et après 
l’administration de la médication. La durée de chacun des comportements spécifiques a été 
compilée à l’aide du logiciel Noldus® et la température corporelle a été prise par 
thermomètre rectal.  Le modèle équilibré de mesures répétées indique que les sujets ayant 
reçu la dextroamphétamine montrent une réduction significative (p = 0.044) de leur 
fréquence cardiaque comparativement aux chiens ayant reçu le placebo.  Aucune variation 
significative n'a été observée concernant la température corporelle, l'activité motrice, et les 
autres comportements (léchage des babines, halètements, et bâillements) suite à 
l’administration de la dextroamphétamine.  Une corrélation significative, linéaire et positive 
(p < 0,0001) entre les périodes de mouvements observées (vidéo) et les mesures d’activité 
enregistrées par l’accéléromètre a été observée.  Les résultats de cette étude indiquent que 
les Beagles peuvent afficher des effets paradoxaux dans les 90 minutes suivant 
l’administration per os de dextroamphétamine à raison de 0.2 mg/kg. 
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Abstract 
Several veterinary behaviour texts/handbooks used in practice, distinguish 
hyperactivity or hyperkinesis from over-activity by using the physiological and behavioural 
responses of dogs given amphetamines. It is presumed that true hyperactive or hyperkinetic 
dogs given 0.2 - 1.0 mg/kg dextroamphetamine orally will paradoxically calm down, and 
have at least a 15% reduction in heart and respiratory rates. The purpose of the study was to 
measure the effects of an oral dose of 0.2 mg/kg dextroamphetamine on heart rate, body 
temperature, motor activity, and discrete behaviour sequences in Beagle dogs. Reliability of 
a collar mounted accelerometer, Actical® as an objective measure of motor activity was 
also investigated.  
The study design was a placebo controlled cross-over study. Twelve research 
colony Beagle dogs (13 - 20 months old) received an oral dose of 0.2 mg/kg 
dextroamphetamine as treatment. Baseline and post-treatment values for body temperature, 
heart rate, motor activity, and general behavioural changes, were obtained using rectal 
temperature, video recordings and Noldus® software, Polar® monitor (heart rate), and a 
collar mounted Actical®. A repeated measures model indicates that dogs receiving an oral 
dose of 0.2 mg/kg dextroamphetamine had a significantly (p = 0.044) reduced heart rate 
compared to placebo. There was no effect of treatment on the dogs’ body temperature, 
motor activity, or other behaviours such as “lip-licking”, “panting” and “yawning”. There is 
a significant linear and positive relationship between the gross motor activity as measured 
by observational video and the Actical® counts (p < 0.0001). Results from this study 
indicate that Beagle dogs may display some paradoxical effects in the 90 minutes following 
an oral dose of 0.2 mg/kg dextroamphetamine. 
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Introduction 
Behaviour problems and unwanted behaviours are common reasons for 
relinquishment of dogs to animal shelters in North America and many of these dogs end in 
euthanasia (Patronek et al. 1995; Patronek et al. 1996). The human-animal bond, although 
very strong and evolving considerably, is not always strong enough to overcome significant 
canine behaviour problems. Owners with dogs suffering from behaviour problems will 
often go to their friends, trainers, and sometimes as a last resort, their veterinarians for 
assistance and advice. Unfortunately the advice given on behaviour problems by trainers 
and the public often relies on anecdotal or media based information instead of science-
based evidence. This is turn can lead to the use of techniques and recommendations that 
could be harmful to the dog possibly even exacerbating or aggravating the behaviour 
problem. As the new specialty of veterinary behavioural medicine evolves and grows, more 
information is being gathered on normal and abnormal behaviours of the canine species as 
well as on humane and effective treatments for these problems. 
As human populations move toward more urban and suburban living conditions, 
dogs are now expected to live often in restrictive environments, with little environmental 
stimulation. With little-to-no data available on what is considered “normal activity” it is 
even more difficult to define hyperactivity.  Is it a question of breed differences (working 
breeds versus non-working breeds), health, environment, lack of exercise, etc.? 
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In human medicine, Attention-Deficit Hyperactive Disorder (ADHD) is among the 
most frequently diagnosed child psychiatric disorder and is estimated to affect 3 - 5% of 
school aged children in North America (Barkley 1996). Canine Hyperactivity or 
Hyperkinesis Syndrome (HS) has been recognized since the 1970’s in veterinary 
behavioural medicine. Owners commonly describe their dogs as being “over-active” or 
“hyper-active”, “difficult to handle”, and “unable to concentrate”. The current definitions of 
canine HS are however highly variable, inconsistent and vague. As a result, it is extremely 
difficult for a veterinarian to diagnose HS in a dog. 
Campbell (1973) was one of the first authors to publish information on HS in the pet 
dog population.  He notes that clinical signs may include rapid heart rate and respiration, 
excessive salivation, a high metabolic rate and reduced urine output. He distinguishes 
between hyperkinesis and hyperactivity of dogs using owner complaints as well as the use 
of a stimulant medication response test. The majority of veterinary behaviour reference 
texts and publications in North America have described the use of this stimulant 
(dextroamphetamine or methylphenidate) response test for the diagnosis of HS and they are 
all based on the initial description made in the 1970’s by Corson. In general, the test 
includes taking baseline physiological parameters such as heart rate and respiratory rate as 
well as objective evaluation of the dog’s activity level. The dog is then given an oral dose 
of dextroamphetamine (0.2 mg/kg – 1 mg/kg) or methylphenidate (0.2 mg/kg up to 1 mg/kg 
for an aggressive dog). If a paradoxical effect occurs then the dog will calm down, and its 
heart rate and respiratory rate will decrease by at least 15% from initial basal rates. This 
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“paradoxical” effect of CNS stimulants is observed 30 - 90 minutes post-administration of 
the medication (Campbell 1992; Overall 1997; Lindsay 2001; Landsberg et al. 2003; Houpt 
2005). 
Practitioners, trainers and the public are often commenting that overactive dogs are 
either genetically predisposed to high levels of energy and activity (working breeds), or 
their “unruly” behaviours have been inadvertently rewarded (or both). Some specialists 
believe that hyperactivity is over diagnosed and that in general these dogs are simply under-
exercised and over-active. Owner questionnaires and temperament tests may be done by 
veterinarians, behaviour specialists, trainers and breeders to obtain information regarding 
activity of the adult dog or puppy as well as other information such as anxiety/nervousness, 
sociability and aggression. These subjective clinical evaluations are not well validated and 
most studies do not address validity issues. Objective measures of activity, such as 
pedometers, accelerometers, and video-tracking devices, are increasingly being used in 
research, however the reliability and validity of these devices is still being questioned. The 
expense of some of these devices will greatly influence their ability to be used in non-
research center settings such as testing dogs in the public and in clinical practice. 
Studies with children have shown that stimulant medications such as 
dextroamphetamine and methylphenidate may produce “paradoxical” effects in both 
normal and hyperactive children. There is a group of non-ADHD children that when given 
amphetamines may become less motor active and may be able to concentrate for longer 
periods of time.  Clinical studies in combination with clinical interpretations in the field, 
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have led investigators and clinicians to question the abundant use of stimulants in the 
treatment of children with ADHD as there is likely a subgroup of children who are not truly 
ADHD and yet still respond paradoxically to stimulants (Zahn et al. 1980). This may be 
leading to the misuse and over-prescription of MPH in some cases of children who are 
clinically not ADHD. 
In contrast to human doctors, it is rare for veterinarians, including veterinary 
behaviour specialists, to prescribe stimulants for the treatment of dogs suspected of 
suffering from HS. Are we as veterinarians’ under-diagnosing, over-diagnosing or 
misdiagnosing this syndrome in dogs? Is this due to poor diagnostic criteria and evidence? 
Or is it due to the common misconception that dogs, like human children, do not have true 
ADHD but rather that they are simply not getting enough exercise and stimulation? 
The primary objective of the present study is to measure the effects of an oral dose 
of dextroamphetamine on Beagles using a clinical diagnostic HS testing regimen. There are 
no clinical trials using the diagnostic regimen outlined in the veterinary behaviour texts and 
publications. What are the effects of this response test on Beagles and do some of these 
dogs just like children, respond paradoxically to amphetamines even when clinically not 
hyperactive or hyperkinetic? 
In the present study, the initial experimental protocol used two different doses: 0.2 
mg/kg as well as 1.3 mg/kg of dextroamphetamine. The first dog to receive the higher dose 
of 1.3 mg/kg displayed stereotypic behaviours 3.5 hours after receiving the oral dose as 
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well as an increase in body temperature to 40°C (personal communication, Dr Diane 
Frank). For reasons of animal welfare, the higher dose regimen was discontinued and the 
lower 0.2 mg/kg dose was maintained for the purpose of this study. 
A secondary objective of the study was to investigate the reliability of an activity 
measuring device: the accelerometer (Actical®). The objective evaluation of motor activity 
in dogs is an area of veterinary medical research that is rapidly expanding, and tools such as 
pedometers, motion sensitive-video tracking and accelerometers may allow for more 
reliable and objective methods of monitoring. Accelerometers have not been used often in 
the study of motor activity in dogs and so we hope that the information collected using this 
device will significantly assist the development of future motor activity studies on dogs in 
at-home contexts. 
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Chapter I - Literature Review 
I.1 Canine Hyperactivity or Hyperkinesis Syndrome (HS) 
I.1.1 Current Definition of Canine Hyperactivity or Hyperkinesis 
Syndrome 
The current definitions of canine Hyperactivity or Hyperkinesis syndrome (HS) are 
highly variable and there is very little recent literature on the subject. In 1973, W. Campbell 
was one of the first to publish information on hyperkinesis in the pet dog population. He 
describes signs associated with this syndrome as those that “are usually displayed when the 
dog is distressed by close confinement and/or social isolation”. Campbell notes that clinical 
signs may include rapid heart rate and respiration, excessive salivation, a high metabolic 
rate and reduced urine output. He distinguishes between hyperkinesis and hyperactivity of 
dogs using owner complaints. Campbell claims that owners with hyperkinetic dogs will 
have complaints such as: “the dog cannot sit still, even for a minute; it never becomes 
accustomed to everyday situations; it cannot learn anything; it salivates constantly and 
always seems excited or nervous”. 
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Lindsay (2001) recommends that dogs that are excessively active and “present with 
signs of impulse-control problems and other relevant symptoms such as attention deficits, 
inability to calm down, and persistent reactivity to restraint and confinement, 
aggressiveness and impaired learning ability and insensitivity to punishment” be evaluated 
for HS. 
At this time, there remains a great deal of debate on the true definition of canine 
Hyperactivity or Hyperkinesis Syndrome (HS). Certain general textbooks/handbooks of 
veterinary behaviour medicine used frequently in North America (Campbell 1992; Overall 
1997; Landsberg et al. 2003) claim that hyperactivity or over activity are not the same as 
true hyperkinesis. These handbooks/textbooks postulate that this hyperactivity (and/or over 
activity) can be differentiated from hyperkinesis based on the response of the patient to a 
test using stimulant medications. Landsberg et al. (2003) discusses that overactive dogs are 
either genetically predisposed to high levels of energy and activity (working breeds), or 
their “unruly” behaviours have been inadvertently rewarded (or both). It is also described 
that true Hyperkinesis or Attention Deficit Syndromes with Hyperactivity in dogs are those 
which exhibit paradoxical responses to stimulant medication tests. 
Other definitions of these types of syndromes are described in some European 
veterinary behaviour manuals and transcripts. Dr Patrick Pageat has described a Syndrome 
called Hypersensitivity – Hyperactivity syndrome (HS-HA). HS-HA has been described as 
a syndrome that occurs when dog’s motor activity appears to be overdeveloped (Landsberg 
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et al. 2003; Pageat, 1998). Some criteria noted by Pageat include absence of bite inhibition 
in a puppy older than 2 months of age, hypervigilance, and in some cases a reduction and 
alteration of the normal sleep patterns of the dog. 
 
I.1.2 Attention Deficit and Hyperactivity in Children 
It is clear from the above discussion, that canine HS-HA as well as HS do not have 
one compelling clinical sign associated with definitive diagnosis. In human literature 
definitions of these disorders have changed significantly over the past 30 years. 
Hyperactivity was initially considered the principle feature of a vaguely defined precursor 
to Attention-Deficit Hyperactive Disorder (ADHD), known as hyperkinetic reaction 
disorder of childhood (American Psychiatric Association 1968). As appears to be the case 
with the canine definitions and diagnostic criteria, the human condition has been redefined 
multiple times. Currently, in the Diagnostic and Statistical Manual of Mental Disorders 
(DSM IV), ADHD is conceptualized as a 2-dimensional disorder, composed of symptoms 
of hyperactivity, impulsivity and inattention (American Psychiatric Association 1994). 
Debate on the most recent definitions of ADHD in humans continues in the psychiatric 
field of medicine. 
ADHD is among the most frequently diagnosed child psychiatric disorders and is 
estimated to affect 3 - 5% of school aged children in North America (Barkley 1996). 
Treatment of ADHD involves support and education of parents, appropriate school 
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placement and pharmacotherapy. Hyperactivity, a central feature of ADHD, is often 
defined in human medicine as excessive or developmentally inappropriate levels of motor 
activity. Restlessness, fidgetiness, squirming in one’s seat and often the appearance of 
being always “on the go” or as if “driven by a motor” are observed (American Psychiatric 
Association 1994). The use of stimulants for treatment is commonplace in human medicine, 
with the most frequently used drug being methylphenidate (short and long acting). A 
double-blind cross-over study done in 1980 by Zahn et al. discovered that 
dextroamphetamine affected both normal and hyperactive boys in a similar way. Both 
groups of children showed on average a reduced motor activity and impulsivity, improved 
attention and reduced heart rate prior to a reaction time test. This study in combination with 
clinical interpretations in the field, have lead investigators and clinicians to question the 
abundant use of stimulants in the treatment of children with ADHD as there is likely a 
subgroup of children that are not truly ADHD and respond paradoxically to stimulants. 
This may be leading to the misuse and over-prescription of methylphenidate in some cases 
of children who are behaviourally not hyperactive. 
 
I.1.3 Factors Influencing Canine Hyperactivity or Hyperkinesis 
Syndrome (HS) 
I.1.3.1 Normal Canine Activity and Testing Methods in Both Humans and Dogs 
  
10
 
Use of the word “over-active” or “hyper-active” is common amongst veterinarians 
and the general public. Owner questionnaires and temperament tests may be done by 
veterinarians, behaviour specialists, trainers and breeders to obtain information regarding 
activity of the adult dog or puppy as well as other information such as anxiety/nervousness, 
sociability and aggression (Jones & Gosling 2005). Categories and labels such as 
“Activity” (Goddard & Beilharz 1984), “Locomotor activity” (Hennessy et al. 2001) and 
“Excitability and Trainability” (Hsu & Serpell 2003) are used in questionnaires and 
temperament tests. These subjective clinical evaluations are not well validated and most 
studies do not address validity issues. The psychometric properties of owner derived 
evaluations or assessments are often not established. Recently a thirteen item rating scale 
questionnaire was developed for dog owners to measure attention deficit and activity-
impulsivity in their dogs (Vas et al. 2007) and its validity and reliability were measured. 
This questionnaire was primarily developed as a “tool for describing the typical responses 
of pet dogs to common stimuli in their natural environment”. Although the study indicates 
that this questionnaire is both valid and reliable, it does not however test for different 
people scoring the questionnaire other than the owners. As in human studies (Mitsis et al. 
2000), there may be poor concordance between different people scoring and this should be 
investigated further. 
A canine study evaluating the relationship among fearfulness, activity and 
exploration of guide dogs at varying ages, identified that as dogs get older their activity in 
the home, as per the dog trainer, was reduced. However, in other contexts such as on a 
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walk, there is only a very small reduction in this type of activity with age (Goddard & 
Beilharz 1984).  Activity level may significantly drop as the dog ages and puppy activity 
may be a weak indicator of adult activity (Goddard & Beilharz 1984; Serpell & Hsu 2001). 
 Aged dogs in a controlled indoor housing setting were found to display fewer hours 
of activity and more rest periods than younger dogs (Siwak et al. 2003). Dogs with age-
related cognitive impairment display more activity than normal aged dogs especially in the 
afternoon which parallels the results seen in human medicine with patients suffering from 
Alzheimer’s disease. The normal sleep-wake cycle in dogs and their activity rhythms also 
appears to be affected by housing type and light-dark transitions (Siwak et al. 2003). 
In the current version of the DSM-IV, there are over 29 disorders that require the 
assessment of altered activity level in people including anorexia nervosa, conduct disorders 
and depression (American Psychiatric Association 1994). To date there is no clear-cut 
objective data on how to define the levels or pattern of normal and hyperactive behaviour. 
Instead, there is wide use of questionnaires to assess attention skills, impulsivity and motor 
activity, as well as many other traits seen in children and in adults. The Conners Teacher 
Rating Scale (CTRS), a validated primary rating scale which in subsection IV scores 
overall activity of children (Conners 1969; Conners 1990) is commonly used in North 
America (Annex I). Other validated human ADHD questionnaires are used based on the 
DSM-IV criteria such as DuPauls ADHD Rating Scale. Current human diagnostic tools will 
include these rating scales as well as other psychometric evaluations and in some cases the 
use of solid-state actigraphs, and pedometers to measure the activity level of the person 
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(Tryon & Pinto 1994). Studies have shown that the use of actigraphs provides a valid and 
reliable measure of activity as well as an objective and independent standard against which 
to test the validity of diagnostic classifications from interviews and questionnaires (Dane et 
al. 2000). 
 
I.1.3.2 Objective Measures of Activity  
In a practical sense, it can be quite difficult to study behaviour of dogs in their 
natural environment. It may be seen as intrusive to the owner, and may be very time-
consuming/laborious. Wilson & Sundgren’s (1998) arena test which measures activities 
based on how many times a puppy or dog crosses a set of grid-lines in an empty arena, is an 
example of one method of measuring motor activity of the dog (Wilson & Sundgren 1998).  
A grid line technique was also used to measure locomotor activity in a study designed to 
predict problem behaviour after adoption (Hennessy et al. 2001). Pedometers and owner-
reported activity were correlated at (r = 0.305) in a study by C.B. Chan et al. (2005). It was 
however found that pedometer accuracy differs with both size of the dog and the dogs gait 
(Chan et al. 2005). 
Motion tracking devices and behavioural computer software that allow for the 
measurement of duration and frequency of chosen behaviours are becoming more common 
in veterinary studies. Observations by investigators can be somewhat subjective, 
particularly when it involves the interpretation of a particular behaviour. The presence of an 
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investigator (in-person/gross observation) may affect the normal behaviour of the animal 
being observed.  The use of videotape recordings allows for continuous recording of 
behaviours, although this is more difficult when light is reduced (such as night-time). Use 
of infra-red lighting to improve video-evaluation has been helpful in these circumstances 
(Tontodonati et al. 2007). Telemetry devices paired with computer tracking systems as well 
as computer-linked video cameras have also allowed for objective method of measuring 
activity (Hansen et al. 2007; Tontodonati et al. 2007). Hansen et al. (2007) used a computer 
movement tracking system to evaluate baseline activity in dogs in an at-home setting. The 
purpose of the study was to determine the correlation between activity as measured by an 
accelerometer and videographic measures of movement and mobility in dogs (Hansen et al. 
2007). The video movement tracking systems will only measure movement with a velocity 
and requires that the animal’s position change over time and does not account for activity 
that occur when the position does not change, such as grooming, shaking head, eating, etc. 
 
I.1.3.3. Accelerometers 
Activity monitoring systems have been used in human activity studies and have 
been shown to reliably measure motor activity in humans. Accelerometers are devices 
which monitor the occurrence and intensity of motion and allow for continuous, objective, 
and quantitative evaluation of physical activities. These devices integrate the amplitude and 
frequency of motion by producing an electrical current that varies in magnitude. These 
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accelerometers are sensitive to movement in all directions. The piezoelectric sensor is the 
functional device of the accelerometer and will generate a voltage change when the device 
is subjected to a change in velocity. This acceleration is filtered and passed into a converter 
system which then creates a digital value. 
The accelerometers themselves will vary somewhat between companies, as to unit 
size and minimal force measured (0.01G – 4.0G). Some accelerometers can be set for the 
minimal threshold force needed to cause an “activity count” as well as the memory of the 
meter (from seconds to minutes). Yamada and Tokuriki (2000), measured spontaneous 
activity in Beagle dogs in a cage setting using an accelerometer and studied the effect of 
movements on activity counts. When the threshold of the accelerometer and the amount of 
acceleration volume were set at 0.10G and 251 or more, then only movements of the 
whole-body and change in posture (such as sitting) were recorded as activity counts. At 
lower thresholds, such as 0.02G, more subtle movements were recorded by the 
accelerometer such as head movement (Yamada & Tokuriki 2000). 
The accelerometers used in veterinary research are presently small in size and light 
in weight. They can therefore be worn easily on various parts of the body using collars or 
vests, and stockings. Hansen, et al. (2007), also investigated the location and method of 
attachment of the accelerometer on the dog. The ventral neck collar mounted accelerometer 
had the highest correlation coefficient (0.88) between activity counts, distance traveled and 
time spent mobile. Other areas, such as the humerus, had lower correlation, suggesting that 
the collar mounted device is likely the best location and is also the most convenient 
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location on the dog. A recent study by Lascelles, et al. (2007) investigated the correlation of 
a neck mounted accelerometer and client-specific measures of pain in cats suffering from 
osteoarthritis in the home setting. A client-specific outcome questionnaire was used to 
determine if the owner had noticed altered activity in their cat (simple yes/no questions). 
This study showed that accelerometers may generate objective data which could be used to 
validate subjective assessments of pain such as outcome questionnaires. The accelerometer 
may also be a useful tool to measure activity of cats in an at-home setting and may be used 
to detect behaviour changes associated with pain in cats (Lascelles et al. 2008). 
The use of objective measurements gives the investigator the added advantage of 
further defining the hyperactivity in terms of quantity and pattern rather than simply 
categorically. The accelerometer however does not provide any information regarding the 
level of co-ordination of movements, the purposefulness, appropriateness or the goal 
directedness of the activity it is recording, which in human studies may be important 
information. Even given its shortcomings objective tools such as the accelerometer can be 
used as an adjunct to conventional diagnostic tools that rely strictly on the subjective 
evaluation of the patient. 
 
I.1.4 Potential Underlying Mechanisms of Canine Hyperactivity or 
Hyperkinesis Syndrome 
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Several amino acids are found in high concentration in the brain, and some have 
been identified as neurotransmitters. Neurotransmitters in the brain include monoamines: 
norepinephrine, dopamine and serotonin (5-HT), and peptides (such as vasopressin). A 
dog’s nervous system activity is a result of interplay between excitatory and inhibitory 
neurotransmitters. Glutamic acid (glutamate) is the major amino acid neurotransmitter for 
fast excitatory synaptic transmission. Gamma-amino-butyric acid (GABA) is the major 
amino acid neurotransmitter for the fast inhibitory synaptic transmission.  Some other 
neurotransmitters, such as dopamine, depend on the receptor at the synapse to determine 
whether the transmitter is excitatory or inhibitory. 
It has been hypothesized that dogs suffering from HS may suffer from a lack of 
neurotransmitters in the inhibitory centers of the brain (Campbell 1992; Lindsay 2001), 
specifically dopamine. In humans, depressed dopamine activity was found in adults with 
ADHD (Volkow et al. 2007). Dopamine and epinephrine are primarily neurotransmitters 
that produce arousal. Dopamine has many functions in the brain including cognition, sleep, 
attention, motor activity and motivation. Cortical inhibitory processes will modulate 
excitatory neuro-activity, keeping motor activity regulated and controlled. These processes 
can be thought of as a “control switch” made of a succession of 3 neurons: a dopaminergic 
neuron coming from the striatum (subcortical part of the cerebrum), and two GABAnergic 
neurons situated in the nucleus accumbens and the ventral pallidum of the brain. These 
neurons then connect with motor-neurons (Lindsay 2001; Dehasse 1999). All these neurons 
are firing spontaneously and inhibit the next neuron, creating an “electrical switch”. As is 
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postulated with people suffering from ADHD, dogs affected by HS may have a lack of 
inhibitory action in the brain and so their “control switch” is often in the “on-position”. 
Animal studies using knockout mice that lacked serotonin (5-HT 1B) receptor 
showed a marked increase in motor activity (Brunner et al. 1999). A selective 5-HT 
reuptake inhibitor, fluoxetine, has been shown to attenuate hyperactivity in knock-out mice 
that lack the gene responsible for encoding the dopamine transporter (Gainetdinov et al. 
1999). These studies have led researchers to continue investigating the role of serotonin 
transporters in ADHD as well as the effects of psychostimulants on serotonin transporters. 
Genetic polymorphism within the dopamine D4 receptor (DRD4) gene has been 
linked to ADHD (Faraone et al. 2005). Given these results, it is thought in humans that 
ADHD is highly heritable (Shaw et al. 2007).  In canine studies, the D4 receptor is also 
thought to be involved in HS, and has been found to be responsible for “novelty seeking” 
behaviours with the long allele having the higher tendency for novelty seeking (Niimi et al. 
1999). 
 
I.1.5 Diagnostic Methods for Canine Hyperactivity or Hyperkinesis 
Syndrome 
Corson and Corson (1976) describe a naturally occurring Telomian-Beagle hybrid 
dog model whose behaviour closely resembled that of children suffering from hyperkinesis 
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(as defined at that time). These Telomian-Beagle hybrid dogs had been shown to exhibit 
hyperactivity, impulsiveness and impaired learning and were unable to be trained in a 
Pavlovian stand either with positive or negative feedback. When Corson and Corson (1976) 
treated these hybrid dogs with dextroamphetamine, they found variability in response to 
treatment. Some of the hybrid dogs began to respond to Pavlovian conditioning while 
others did not. These responders also displayed some physiological changes as well as 
behaviour changes with the stimulant medication. The “hyperkinetic” amphetamine 
responder dogs became “normalized” and trainable with dextroamphetamine doses of 0.2 - 
1.0 mg/kg per os (Arnold et al. 1973; Corson & Corson 1976; Corson et al. 1980). 
Approximately 60% of dogs which were classified as being hyperkinetic responded 
paradoxically to stimulants. These studies allowed for the use of dogs as a model for 
hyperkinesis in children as well as pursue further investigation of the disorder in the canine 
species. 
All present literature refers back to the Corson et al. studies and it was on the basis of 
these studies that Campbell in 1973, developed a preliminary clinical test for hyperkinesis 
which has since repeatedly been recommended in many behaviour texts. This test has not 
been validated. The procedure is as follows: 
1. “Without the client present the dog’s pulse and respiration are recorded in the 
smallest examination room available. 
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2. Salivations (heavy, light, none) are noted and the client is questioned about the dogs 
urination pattern for evidence of antidiuresis. 
3. Muscle tone and general activity are noted. 
4. Oral dextroamphetamine is administered at a dose of 0.2 mg/kg orally and then the 
dog is taken to a holding area. 
5. After 75 minutes minimum, and using a different small examination room, the 
pulse, respiratory, salivation and muscle tone and general activity are recorded. 
6. If the dog displays higher readings and increased muscle tone and activity it is 
presumed the amphetamine has produced normal response and the dog is not 
hyperkinetic. If the opposite is true, the dog is likely hyperkinetic.” (Campbell 
1973). 
Luescher (1993) repeated the Campbell test with 6 cases and remarked that paradoxical 
effects were often seen as early as 30 minutes after receiving the oral dextroamphetamine. 
Campbell (1992) and Overall (1997), state that dogs may be diagnosed as hyperkinetic if 
they have a ≥ 15% decrease in heart rate and respiratory rate 75 - 90 minutes after receiving 
0.2 - 1.0 mg/kg of methylphenidate. Houpt (2005) recommends a dose of 0.5 mg/kg of 
amphetamine (not specified as to which amphetamine should be used) and then repeating 
heart rate and respiratory measures 30 to 60 minutes after receiving the medication. 
Landsberg et al. (2003), also recommends the stimulant test, at a dose of 0.2 - 0.5 mg/kg of 
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dextroamphetamine and monitoring effect every 30 minutes for 2 hours. Houpt (2005) and 
Landsberg et al. (2003) do not define the amount of reduction in respiratory rate, activity, 
or heart rate necessary to diagnose hyperactivity. 
Other sources use response of a trial treatment of amphetamines as a diagnostic method. 
Voith (1980) recommends simply doing a trial with the stimulant medication and gradually 
increasing the dose by small increments until effective dose is reached.  Landsberg et al. 
(2003) also recommends the use of an oral low-dose of methylphenidate at 0.5 mg/kg twice 
daily with increasing increments of 0.25 mg/kg to effect up to a maximum of 2 mg/kg twice 
daily. 
 
I.1.6 Therapeutic Management of Canine Hyperactivity or Hyperkinesis 
 Syndrome 
Management of HS has generally encompassed two areas of therapy: behaviour and 
environmental modification as well as pharmacological treatment. References will describe 
either simply using behaviour modification or using a combination of both pharmaceutical 
intervention and behaviour modification. Some references will determine which therapy to 
use depending on the response of the patient to a stimulant trial (see I.1.5). In all references, 
behaviour modification is always an integral part of treatment, with or without 
pharmacological intervention. 
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I.1.6.1 Behaviour Modification and Environmental Modification 
Various forms of behaviour modification have been outlined as sole or adjunct 
therapy for dogs suffering from HS. Some sources, such as Overall (1997), claim that true 
hyperkinesis is rare and in such cases, behaviour modification is generally the sole 
treatment option.  Landsberg et al. (2003) discuss canine hyperactivity concomitantly with 
unruliness and outline the need for increased exercise and play when treating these 
problems. 
Common veterinary behaviour references such as Voith (1980), Houpt (2005), 
Landsberg et al. (2003), and Overall (1997), discuss behaviour modification for HS cases 
with congruency. Voith (1980) summarizes a group of behaviour modification techniques 
to be employed with “playful aggressive behaviour or hyperactivity”. She recommends the 
single or combined use of methods such as extinction (ignoring the activity until it 
extinguishes itself), re-direction (re-directing the dog from exuberant inappropriate 
behaviours to a more acceptable behaviour), counter-conditioning (teach the dog a response 
that is incompatible with the undesirable behaviour) and punishment.  Houpt (2005) 
outlines that if the dog is fine in the absence of the owner then increased exercise, a canine 
companion, and training may suffice to improve the dog’s behaviour. The positive 
reinforcement of calm behaviours is also mentioned in many references. Landsberg et al. 
(2003), focus on the unintentional and inadvertent reinforcement of undesired exuberant 
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and attention seeking behaviours by the owners. Extinction techniques and deference 
programs are therefore recommended as behaviour modification techniques. There are no 
studies to date that investigate the efficacy of any of the above behaviour modification 
techniques. Pageat (1998) recommends the use of “therapy by games” and learning 
programs to teach dogs social inhibitions. For example, if when playing a game with the 
dog, it begins to engage in behaviour other than the game itself (such as jumping on the 
person), then Pageat recommends cessation of any interaction with the dog. In general, 
Pageat will recommend beginning pharmacological treatment for a minimum of 3-4 weeks 
before initiating behaviour modification, to ensure the dog’s overall activity is bearable by 
the owners (Pageat 1998). The use of pharmacological treatment prior to the initiation of 
behaviour modification has not been validated. 
 
I.1.6.2 Pharmacological Treatment 
Most psychotropic medications used in the treatment of HS are based on the 
hypothesized underlying neuro-chemical mechanism of this syndrome. As will be discussed 
later (section II.2), dextroamphetamine and other stimulants such as methylphenidate, will 
affect certain neurotransmitters and either prevent their re-uptake and/or cause them to 
increase stimulation of post-synaptic receptors (Patrick & Markowitz 1998). Stimulant 
medications have been recommended by authors for the treatment of HS however the 
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discussion of their efficacy and long-term use is questioned by many of these same authors 
(Overall 1997; Lindsay 2001; Landsberg et al. 2003). 
Campbell (1973), recommends using 0.2 mg/kg dextroamphetamine three times 
daily and to increase the dose of the medication by 50% on consecutive days until the 
desired response is achieved.  Cases reported by Campbell (1992), report therapeutic doses 
ranging from 0.5 - 1 mg/kg. Luescher (1993) describes the use of dextroamphetamine for 
the six canine HS cases reported at doses between 0.2 - 0.5 mg/kg dextroamphetamine as 
trial, however he also discusses the use of tricyclic anti-depressants (TCA), and 
methylphenidate for dogs who do not respond paradoxically to dextroamphetamine. 
Landsberg et al. (2003), recommend using methylphenidate at low doses of 0.5 mg/kg 
twice daily and gradually increasing the dose by 0.25 mg/kg increments every 2 days until 
the desired response is achieved up to a maximum dose of 2 mg/kg twice daily. 
The effectiveness of amphetamines (dextroamphetamine and methylphenidate) in 
controlling HS may be partly due to the release of 5-HT (serotonin), either directly or via 
action of released dopamine at 5-HT neurons. As such, SSRIs (selective serotonin reuptake 
inhibitors) such as fluoxetine hydrochloride and TCAs such as clomipramine hydrochloride 
have also been recommended for treatment in some cases (Voith 1980b; Luescher 1993; 
Lindsay 2001; Landsberg et al. 2003). Dehasse (1999) and Pageat (1998) claim that 
because a lack of dopamine may be causing overactivity at the control switch in the brain, 
treatment with inhibitors of monoamine oxidase (MAO), such as selegiline for HA-HS 
dogs may be beneficial. Selegiline prolongs the effects of dopamine in the brain by 
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preventing its breakdown. It is stipulated, however, that the treatment effect of selegiline 
with dogs suffering from HA-HS may be in part due to the fact that selegiline is partly 
metabolized to methamphetamine and l-amphetamine. In other cases, Pageat (1998) also 
recommends the use of normothymic (mood stabilizer) medications such as valproic acid 
and carbamazepine. It is important to note, that none of these pharmacological treatments 
have been validated in peer reviewed publications. 
   
I.2 Dextroamphetamine (S)-1-phenylpropan-2-amine sulfate 
Dextroamphetamine (dexamphetamine, d-amphetamine) is the dextrorotary 
stereoisomer of the amphetamine molecule which can take 2 forms: d-isomer and l-isomer 
(Baggot & Davis 1973). 
 
I.2.1 Mechanism of Action 
The exact mechanism of action of dextroamphetamine is unknown. Studies describe 
its actions as stimulating central nervous system activity, blocking reuptake and increasing 
release of norepinephrine (sympathomimetic) and dopamine in extra-neuronal space. 
Dextroamphetamine affects dopamine and serotonin levels in the nucleus, and 
norepinephrine in the hippocampus of the brain (http://en.wikipedia.org/wiki/ 
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Hippocampus). Dextroamphetamine is a substrate analog at monoamine transport, and 
regardless of dose, it prevents the reuptake of the monoamine neurotransmitters causing 
them to remain in the synaptic cleft for prolonged periods (Kuczenski et al. 1995). When 
doses are high, dextroamphetamine will enter nerve cells and cause release of monoamines 
from the cytoplasmic dopamine pool. In such high concentrations, dextroamphetamine will 
cause the norepinephrine, dopamine, and 5-HT transporters to reverse their direction of 
flow. This inversion leads to a release of these transmitters from the vesicles to the 
cytoplasm and from the cytoplasm to the synapse causing increased stimulation of post-
synaptic receptors (Patrick & Markowitz 1998). Overall, their stimulant action is produced 
by releasing catecholamines from adrenergic nerve terminals, inhibiting re-uptake of 
catecholamines into storage sites, releasing 5-HT and dopamine from pre-synaptic 
terminals, inhibiting MAO, and also by preventing monoamine reuptake (Diniz et al. 2003). 
  
I.2.2 Pharmacokinetics of Dextroamphetamine 
In humans the primary site of pre-systemic metabolism is likely to be the gut and/or 
intestinal wall. There is little information available in the literature on the site of pre-
systemic metabolism in the dog as compared to the human metabolism. In the canine 
species, the biological half-life of dextroamphetamine was found to be 4.5 +/- 0.24 hours 
(Baggot & Davis 1973). Approximately 1/3 of dextroamphetamine will be excreted 
unchanged in urine in dogs which differs from humans where the percentage is closer to 
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50% (Baggot & Davis 1973). The renal clearance in dogs suggests that the extent of re-
absorption increases with increased urinary pH. The other 2/3 of dextroamphetamine is 
broken down into various metabolites such as benzoic acid. The main metabolic pathway is 
dextroamphetamine  phenylacetone benzoic acid  hippuric acid. Another 
pathway, mediated by enzyme CYP2D6, is dextroamphetamine  p-hydroxyamphe-
tamine  p-hydroxynorephedrine. It does not appear that the extent of plasma protein 
binding significantly affects the pharmacokinetics of this drug in the dog (Baggot & Davis 
1973). 
Maximal plasma concentrations (Cmax) of dextroamphetamine were achieved in 
male dogs between 1 - 2 hours following a single oral doses of 1.5 mg/kg (Bareggi et al. 
1978). The plasma concentration of dextroamphetamine remaining at 8 hours in this study 
following a dose of 1.5 mg/kg was approximately 20% of Cmax (Bareggi et al. 1978). 
Behavioural effects of dextroamphetamine in humans are increased by larger doses, 
however, over the course of a given dose there is a divergence between such effects and 
drug concentration in the blood (Angrist et al. 1987). In particular, mental effects peak 
before maximal blood levels are reached, and decline as blood levels remain stable or even 
continue to increase. 
Bareggi et al. (1979) found that behavioural responses of the Telomian-Beagle 
hybrid dogs depended on the amount of plasma amphetamine which in turn was linearly 
related to the amount in the CNS. It appears that amphetamine peaks and is eliminated from 
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the CSF at the same time as it is in blood plasma (Bareggi et al. 1979a). In these studies, 
responder dogs had higher and earlier peak levels of amphetamine than non-responder dogs 
(Bareggi et al. 1978; Bareggi et al. 1979a). Responder dogs were those Telomian-Beagle 
hybrid dogs that responded in a paradoxical manner to amphetamine (dogs able to respond 
with appropriate behaviour to certain training tests which they were unable to perform prior 
to medication). In these studies there was another group identified as the non-responder 
Telomian-Beagle. These non-responder dogs were unable to perform during training tests, 
even after receiving amphetamine. 
 
I.2.3 Paradoxical Effect of Dextroamphetamine 
Pharmaceutical paradoxical effects are those that exhibit inexplicable or 
contradictory effects. The clinical appearance of paradoxical effects with 
dextroamphetamine is the basis behind the treatment of certain psychiatric disorders with 
these medications. The dose of dextroamphetamine necessary for the “paradoxical” effect 
to be observed in HS dogs is not known. In general dextroamphetamines in the normo-
active dog may cause increased stereotypic behaviours (Randrup & Munkvad 1967), CNS 
excitation, cardiovascular effects (tachycardia), hyperthermia, and some gastrointestinal 
effects (Bareggi et al. 1978; Tontodonati et al. 2007). 
As discussed earlier in sections I.2.1 and I.2.2, stimulants may cause a reduction in 
clinical signs of HS through various neurochemical processes. Once given 
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dextroamphetamine, dogs that display reductions in heart rate, motor activity, respiratory 
rate and body temperature are labelled as displaying paradoxical effects of this medication. 
I.2.4 Clinical Applications of Dextroamphetamine 
Primarily, dextroamphetamine is used to treat ADHD and narcolepsy in humans. 
Stimulants are used to treat people and children suffering from ADHD in an attempt to 
decrease inattention and to increase self-control.  In some countries dextroamphetamine has 
replaced methylphenidate as the first-choice medication for ADHD, a role in which it is 
considered highly effective. During the treatment of narcolepsy, patients will often 
experience tolerance to the therapeutic effects of stimulants (Kaplan & Sadock 1993). 
Dextroamphetamine and other sympathomimetics may also be used to treat depression in 
people that are treatment resistant or if commonly used antidepressants are contraindicated. 
Patients may be placed on sympathomimetics if the risk of adverse effects from TCAs or 
tetracyclic antidepressants and MAO inhibitors is high such as with the elderly. In some 
cases, dextroamphetamine will be used to differentiate human geriatric pseudo-demential 
depression from true dementia. If they respond positively to the stimulant therapy then they 
are presumed to suffer from depression and not dementia. The long term use of stimulants 
to treat depression is controversial because of the potential for abuse of the drugs (Kaplan 
& Sadock 1993). 
In behavioural veterinary medicine the most common therapeutic use of 
dextroamphetamine is for canine HS, narcolepsy, and aggression (if related to HS). The 
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doses recommended for treatment of HS have previously been discussed. In the treatment 
of canine narcolepsy, the dose of 5 – 10 mg dextroamphetamine three times daily has been 
recommended (Allen et al. 1998). 
 
I.2.5 Contraindications and Adverse Effects  
Dextroamphetamine, a CNS stimulant, is generally contraindicated in humans and 
animals suffering from cardiovascular disease, diabetes mellitus, anxiety, glaucoma, 
hypertension, concurrent MAO therapy and those suffering from hyperthyroidism 
(Canadian Pharmacists Association 2007; Crowell-Davis 2006). In humans, cardiovascular 
adverse effects such as palpitations, tachycardia, and hypertension may be seen. Effects on 
the CNS may include overstimulation, restlessness, dizziness, euphoria, dysphoria, and 
headache, exacerbation of motor or other tics, and rarely psychotic episodes. In humans it 
has also been shown to cause diarrhea, loss of appetite, constipation and dry-mouth 
(Canadian Pharmacists Association 2007). In 2006, GlaxoSmithKline Inc., manufacturer of 
Dexedrine® (dextroamphetamine sulfate) made revisions to the warning label of the 
product. The warnings describe reports of sudden death in association with CNS stimulant 
treatment at usual doses in children and adolescents with structural cardiac abnormalities or 
other serious heart problems. As per GlaxoSmithKline (2006) “although some serious heart 
problems alone carry an increased risk of sudden death, stimulant products generally should 
not be used in children or adolescents with known serious structural cardiac abnormalities, 
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cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that 
may place them at increased vulnerability to the sympathomimetic effects of a stimulant 
drug”.  
Amphetamines have been implicated as a potential source of thrombocytopenia in 
dogs (Allen et al. 1998). 
It is hypothesized that patients that do not suffer from HS will exhibit increased 
arousal and activity with dextroamphetamine. In dogs, it appears that dextroamphetamine at 
doses of 1 - 2 mg/kg may induce various stereotyped behaviours, including bobbing, head 
turning, circling, pacing and sniffing (Wallach et al. 1971). Canine case reports of 
amphetamine intoxication from the Veterinary Hospital of the University of Minnesota 
observed hyper-excitability and agitation within 1 - 2 hours after ingestion (Stowe et al. 
1976). A 90-day oral gavage canine toxicity study of d- and d, l-methylphenidate found 
there to be no-observed-adverse-effect at doses of methylphenidate up to 3 mg/kg. At 
higher doses (up to 20 mg/kg), side-effects such as reversible salivation, hyperactivity and 
diarrhea were seen (Teo et al. 2003). Healthy Beagle dogs displayed stereotypic behaviours 
peaking 2.5 hours and 6 hours post administration of amphetamine orally (2.5 mg/kg) 
(Bareggi et al. 1978). This study also found that normal Beagle dogs suffered from 
increased body temperature with peak temperatures at 1.5 hours post-administration of 
amphetamine suggesting that temperature changes are directly related to the presence of 
amphetamine in the plasma. It is postulated that the later peak of stereotypy seen in these 
  
31
 
dogs may be a result of the amphetamine metabolite p-hydroxy-amphetamine (Bareggi et 
al. 1979b). 
A recent study performed by Tontodonati et al. (2007) discovered results similar to 
those described above. The Beagle dogs’ heart rate increased significantly at 1.5 mg/kg of 
dextroamphetamine, between 1 and 20 hours after treatment. At lower doses of 0.25 mg/kg 
and 0.75 mg/kg there was no effect on heart rate. Body temperature was found to increase 
significantly with the dextroamphetamine doses of 0.75 and 1.5 mg/kg (up to 1.2 and 
2.5 °C, respectively), but no significant change at 0.25 mg/kg. No significant change in 
behaviour for most dogs receiving low dose of 0.25 mg/kg was seen, however one dog at 
this dose did show excitement with vocalizations and stereotyped circling between 0.5 and 
2 hours after dosing. At 0.75 and 1.5 mg/kg all dogs showed excitement associated with 
hypersalivation and vocalization and these changes mainly occurred between 0.5 and 
14 hours after dosing. It is unclear from the study results what percentage of dogs in the 
study actually displayed stereotypic behaviours and at which dosing regimen. It was noted 
however that dogs displayed individual tendencies with respect to which stereotypy they 
would display. Stereotypic behaviours noted included: circling, fly snapping, head bobbing, 
repetitive standing, lateral movements and repetitive forward and backward pacing. 
(Tontodonati et al. 2007). 
In studies using “normal” dogs trained to pedal press for drinking water in a non-
cued, single-spatial alternation task (SSA), doses of 0.15 - 0.60 mg/kg of dextroamphe-
tamine, caused a decrease in the total number of correct responses and an increase in the 
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total number of incorrect responses in a dose-dependent manner (Risner & Jones 1979).  
This study suggests that some dogs may respond behaviourally in a dose-dependent way to 
low doses of dextroamphetamine. 
The co-administration of sympathomimetics (such as dextroamphetamine) with 
TCAs, warfarin, primidone, phenobarbital, phenytoin, or phenylbutazone, will decrease the 
metabolism of these compounds and result in increased plasma levels of the non-
sympathomimetic drug. In general it is not recommended that amphetamines be given with 
or within 2 weeks of administration of MAO inhibitors (Kaplan & Sadock 1993). 
In the case of overdose, gastric lavage or activated charcoal is recommended. 
Sedatives such as chlorpromazine and acepromazine (found commonly in veterinary 
facilities in North America) are also recommended to reduce CNS excitation resulting from 
overdose of amphetamines (Canadian Pharmacists Association 2007; GlaxoSmithKline. 
2006). Other sources indicate the use of diazepam at a total dose of 2.5 - 20 mg IV for 
dextroamphetamine overdose (Allen et al. 1998). Increasing renal excretion of the 
medication by acidifying the urine is controversial and not recommended at this time. 
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II.1 Abstract 
Objective: The purpose of the study was to measure the effects of 0.2 mg/kg 
dextroamphetamine on body temperature, heart rate, motor activity, and associated 
behavior changes in Beagles. Reliability of a collar mounted accelerometer as an objective 
measure of motor activity was also investigated by comparing motor activity to that 
observed using video recordings. 
 
Design: Placebo controlled cross-over study 
 
Animals: 12 research colony Beagle dogs (13-20 months old) 
 
Procedures: Beagle dogs served as their own control receiving both placebo and 0.2 mg/kg 
dextroamphetamine as treatment. Baseline and post-treatment values for body temperature, 
heart rate, and motor activity, were obtained using a rectal temperature, heart rate monitor, 
and a collar mounted accelerometer. Behavior sequences were filmed and analyzed. 
 
Results: Repeated measures model indicates that dogs receiving 0.2 mg/kg 
dextroamphetamine had a significantly (P = 0.044) reduced heart rate compared to placebo. 
There was no effect of treatment on the dogs’ body temperature, motor activity or other 
behaviors such as “lip-licking”, “panting” and “yawning”. There was a significant linear 
  
35
and positive relationship between the gross motor activity as measured by observational 
video and the accelerometer counts (P < 0.0001). 
 
Conclusion and Clinical Relevance:  Several behavioral textbooks used in clinical 
practice distinguish canine hyperactivity-hyperkinesis from over-activity by physiological 
and behavioral response to amphetamines in a clinical setting. These authors suggest that 
true hyperactive-hyperkinetic dogs given oral amphetamines will paradoxically calm down, 
and have more than a 15% reduction in heart rate. However no data exist on the various 
effects of a low dose (0.2 mg/kg) of oral dextroamphetamine in dogs. The results of this 
study indicate that although as a group the medicated dogs showed a significantly lower 
heart rate than the placebo group, individual Beagle dogs showed variability in changes of 
heart rate. The use of the accelerometer in this study shows that it is a reliable tool for 
measuring motor activity in the dog. 
 
II.2 Introduction 
Canine Hyperactivity or Hyperkinesis Syndrome (HS) has been recognized since 
the 1970’s in behavioral and veterinary medicine.1-6 Owners commonly describe their dogs 
as being “over-active” or “hyper-active”, “difficult to handle”, and “unable to concentrate”. 
The current definitions, however, of HS are highly variable, inconsistent and vague. In 
1973 Campbell was one of the first to publish information on HS in the pet dog 
population.1 He noted that clinical signs may include rapid heart rate and respiration, 
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excessive salivation, a high metabolic rate and reduced urine output. He distinguished 
between hyperkinesis and hyperactivity of dogs using owner’s complaints. Campbell 
claimed that owners with hyperkinetic dogs would have comments such as: “the dog cannot 
sit still, even for a minute; it never becomes accustomed to everyday situations; it cannot 
learn anything; it salivates constantly and always seems excited or nervous”. 
 
Use of the words “over-active” or “hyperactive” are common among veterinarians 
and the general public. Owner questionnaires and temperament tests may be carried out by 
veterinarians, behavior specialists, trainers and breeders to obtain information regarding 
activity of the adult dog or puppy as well as other information such as anxiety, nervousness, 
sociability and aggression. Categories and labels such as “Activity”7 and “Locomotor 
activity”8 and “Excitability and Training”9 are used in such questionnaires and temperament 
tests. These subjective clinical evaluations are not well validated and most studies do not 
address validity issues.10 Psychometric properties of owner derived evaluations or 
assessments are often not established. Objective measures of activity are often difficult to 
make quantitatively and more research is needed to assess new techniques. 
 
At present time, there remains a great deal of debate on the true definition of Canine 
HS. Certain general texts of veterinary behavioral medicine used in North America claim 
that hyperactivity or over activity are not the same as true hyperkinesis.4,6,11  One author4 
asserts that overactive dogs are either genetically predisposed to high levels of energy and 
activity (working breeds), or their “unruly” behaviors have been inadvertently rewarded (or 
both). Overall6 states that hyperactivity is over diagnosed and that in general these dogs are 
  
37
simply under-exercised and over-active. Many authors3-6,11 postulate that canine 
hyperactivity (and/or over activity) can be differentiated from true HS based on the 
response of the dog to a challenge test using stimulant medications, such as 
dextroamphetamine or methylphenidate. The recommended stimulant-response tests for HS 
vary somewhat between authors. In general, the recommended test although not validated 
includes taking baseline physiological parameters, such as heart and respiratory rates as 
well as objective evaluation of the dog’s activity level. The dog is then given an oral dose 
of dextroamphetamine (0.2 mg/kg - 1.3 mg/kg) or methylphenidate (0.2 mg/kg - 1 mg/kg). 
If the dog calms down, and its heart rate and respiratory rate decrease by at least 15% from 
initial basal rates, this is referred to as a paradoxical effect of CNS stimulants. The criteria 
for this test suggest that a “paradoxical” effect would be observed 30 - 90 minutes post-
administration of the medication.6,11,12 Two authors3,4 did not specify an amount of 
reduction in heart rate, respiratory rate or behaviors, except to note that they would 
generally be reduced if a paradoxical effect was seen. However to the authors’ knowledge 
there is no published data on the various effects of a low dose (0.2 mg/kg) of oral 
dextroamphetamine in dogs. Given that the starting dose of the recommended stimulant test 
for HS is 0.2 mg/kg investigating the effects of this dose on dogs would be of significant 
interest. 
 
The primary purpose of this study was to measure the effects in Beagles of an oral 
dose of 0.2 mg/kg of dextroamphetamine on body temperature, heart rate, motor activity, 
and associated changes in behavior. It was hypothesized based on prior studies13,14  that the 
accelerometer would positively predict the activity measured by observational studies. 
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Therefore the reliability of a collar mounted accelerometer as an objective measure of 
motor activity in the dog was also investigated. 
 
II.3. Materials and Methods  
II.3.1 Subjects 
A total of 12 intact Beagle dogs, 6 males and 6 females, belonging to the animal 
care facility of the Faculty of Veterinary Medicine, and ranging in age from 13 to 20 
months were used for the study.  Physical examination of all Beagles included in the study 
was unremarkable. The study protocol followed Canadian Council on Animal Care 
guidelines and was approved by the Animal Care Committee of the Faculty of Veterinary 
Medicine. 
II.3.2 Study design 
A placebo controlled cross-over study was performed (Figure 1) allowing for the 
collection of baseline, placebo and treatment data for all 12 dogs. A crossover study is one 
in which two or more treatments are applied sequentially to the same subject. The 
advantages are that each subject then acts as its own control and so fewer subjects are 
required. All data were collected in the same room and by the same person over a period of 
one month. Following a 90 minute baseline data collection, dogs received either 
dextroamphetamine (0.2 mg/kg) or placebo treatment. The dextroamphetamine was placed 
in a teaspoon of highly palatable canned food and the placebo entailed simply giving a 
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teaspoon of the same food without any medication. In Sequence 1 (placebo; medication), 
dogs 1 to 6 received one placebo treatment on Day 0 and one dextroamphetamine treatment 
(0.2 mg/kg) 10 to 14 days later.  In Sequence 2 (medication; placebo), dogs 7 to 12 received 
one dextroamphetamine treatment (0.2 mg/kg) on Day 0 and received one placebo 
treatment, 10 to 14 days later.  The minimal interval between treatments was set at 10 days 
based on the estimated wash-out time of dextroamphetamine in dogs and multiplying this 
time by 10 and then doubling that time. Using first order principles, elimination of a drug is 
near complete after 4 - 5 passes of the estimated half-life of the drug15 which for 
dextroamphetamine in the dog was previously found to be 4.5 hours +/ 0.24.16 
II.3.3 Data collected 
II.3.3.1 Body Temperature 
Baseline rectal temperatures were recorded at time 0, then at 90 minutes just prior to 
the administration of placebo or medication and then again at 180 minutes (90 minutes after 
treatment). 
 
II.3.3.2 Heart Rate 
A chest mounted heart rate monitora (Figure 2) at time 0 was attached on a strap 
fitted around each dog’s thorax in the axillary region. The monitor collected a reading of 
heart beats per minute every 5 seconds over the duration of the study periods. These results 
were downloaded to a computer after each 90 minute testing period. 
 
II.3.3.3 Video Analysis and Behavioral Categories 
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Each dog was filmed for two 90 minute periods (180 minutes total) by the same 
person.  This person did not interact with the dogs even if the dogs tried to solicit attention. 
Video-recorded behaviors were compiled using computer softwareb and were reviewed by 
one person who was blinded throughout the study. Behavioral classifications are outlined in 
Table 1. The category of Gross Motor Activity included mutually exclusive observations of 
“immobile”, “locomotion”, “exploration”, “not-visible” and “other”, measured as state 
events (duration). Facial behaviors included “lip-licking”, “panting”, “yawning”, “not-
panting”, and “not-visible”. “Yawning” and “lip-licking” were tabulated as point events 
(frequency) whereas “panting”, “not-panting” and “not-visible” were measured as state 
events. 
 
II.3.3.4 Accelerometer 
All dogs were fitted with a collar that had a mounted accelerometerc (Figure 3). The 
accelerometer is a physical activity monitoring system, which integrates the amplitude and 
frequency by producing an electrical current that varies in magnitude. The accelerometer is 
omni-directional and senses any motion with a minimal force of 0.01G. It is most sensitive 
to movement in the direction parallel with the longest dimension of the accelerometer case. 
The ventral portion of the neck collar was found to be the best location for the 
accelerometer location.13 Measurement period used in this study was set at every 15 
seconds. Every 15 seconds the voltage generated within the accelerometer was compressed 
and converted into an integer and reported as an activity count. The data was then 
downloaded to a computer by placing the accelerometer unit into a telemetric reader after 
each study period. 
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II.3.3.5 Statistical Analysis 
To evaluate the effect of treatment in this placebo controlled cross-over study, 
balanced repeated measures models were used for the following data: temperature, heart 
rate, accelerometer counts, and some observational results (percentage time spent 
“immobile”, time spent “exploring”, and frequency of “lip-licking”). The balanced repeated 
measures model used treatment (placebo versus medicated) as the repeated factor, the 
sequence of treatment (Sequence 1 and Sequence 2) as a nest factor, and baseline measures 
as a co-factor (to control for possible differences among individuals in baseline values). For 
less frequent observations, the Cochran-Mantel-Haenszel test for repeated measures was 
used to evaluate effect of treatment. These observations included: “panting” (used as an 
event due to sample size and frequency), “yawning” (frequency), and “locomotion”. A 
mixed regression model, with dog identity as a random factor, was used to evaluate the 
relationship between the collar mounted accelerometer counts as a measure for activity and 
the observational data on percentage time spent “mobile” (“exploration” + “locomotion”), 
time spent “immobile” and “other” (“non-visible” and “other”). 
 
 
II.4 Results 
II.4.1 Body Temperature 
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A positive and significant effect was found of baseline values on post-treatment 
values (dogs receiving placebo or medication at 90 minutes) (P < 0.0001). There was no 
significant effect of sequence (P = 0.90). These two results suggest that dogs allocated to 
Sequence 1 (placebo; medication) and Sequence 2 (medication; placebo) did not differ in 
temperature values overall and that post-treatment temperature values needed to be 
corrected with baseline values (baseline temperatures predicted post-treatment 
temperatures). There was no significant effect of medication (0.2 mg/kg 
dextroamphetamine) on body temperature with all sequences confounded (P = 0.18). In 
Sequence 1 (placebo; medication) there was no significant effect (P = 0.39) of medication; 
however in Sequence 2 (medication; placebo), the medicated temperatures were 0.13°C 
higher than the mean temperature of the placebo group (P = 0.016). (Figure 4). 
 
II.4.2 Heart rate 
Results show there is a significant effect of medication (0.2 mg/kg 
dextroamphetamine) on heart rate, with the medicated groups heart rates (mean = 99.07 
bpm, SEM = 4.3128) being significantly (P = 0.044) lower than placebo group (mean = 
112.35 bpm, SEM = 4.3128) (Figure 5). The results do indicate that although as a group the 
medicated dogs showed a significantly lower heart rate than the placebo group, individual 
dogs showed variability in heart rate (seven dogs showed more than 15 % decrease in heart 
rate, the decrease ranging from 16 to 34%; one dog showed more than 15 % decrease 
regardless of treatment). This effect of medication was independent of the sequence (P = 
0.81). There was no significant effect of baseline values on post-treatment heart rate values 
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(P = 0.11) and no significant effect of sequence (P = 0.54). These two results indicate that 
individuals allocated to the two sequences of treatments, Sequence 1 (placebo; medication) 
and Sequence 2 (medication; placebo) did not differ in heart rate values overall and that 
post-treatment heart rate values did not need to be corrected with baseline values. 
 
II.4.3 Video analysis 
II.4.3.1 Percentage of time spent “immobile” 
The results show that there was no significant effect of treatment (P = 0.11); dogs 
receiving dextroamphetamine 0.2 mg/kg did not spent more or less time “immobile” when 
compared to dogs receiving placebo. These results were independent of the sequence of 
treatments (P = 0.39). Baseline values predicted post-treatment values significantly (P = 
0.001) but they were not affected by sequence (P = 0.16) and so post-treatment values 
needed to be corrected for baseline values. 
II.4.3.2 Percentage time spent “exploring” 
There was no significant effect of treatment (P = 0.11) and these results were 
independent of the sequence of treatments (P = 0.35). Baseline values predicted post-
treatment values significantly (P = 0.001) but they were not affected by sequence (P = 
0.26) and so post-treatment values needed to be corrected for baseline values. 
II.4.3.3 Frequency of “locomotion” 
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“Locomotion” was not very frequently observed and so the data were analyzed as 
prevalence (did the dog move or not during the observation time). The Cochran-Mantel-
Haenszel test for repeated measures indicated that the prevalence of locomotion did not 
differ statistically between the two treatments (P = 0.48). Pre-treatment prevalence also did 
not differ statistically between groups (P = 0.41). 
II.4.3.4 Frequency of “lip-licking” 
There was no significant effect of treatment (P = 0.89) and the results were 
independent of the sequence of treatments (P = 0.47). Baseline values predicted post-
treatment values significantly (P = 0.02) but they were not affected by sequence (P = 0.09) 
and so post-treatment values needed to be corrected for baseline values. 
II.4.3.5 Frequency of “panting” 
“Panting” was not very frequently observed and so the data were analyzed as a 
prevalence (did the dog pant or not during the observation time). The Cochran-Mantel-
Haenszel test for repeated measures indicates that the prevalence of “panting” did not differ 
statistically between the two treatments (placebo and medicated) (P = 1). This was also the 
case for the frequency of “panting” in pre-treatment groups. “Panting” appeared to be less 
prevalent in the two post-treatment groups (a decrease from 66.7% to 16.7%). 
II.4.3.6 Frequency of “yawning” 
The Cochran-Mantel-Haenszel test for repeated measures indicated that the 
prevalence of yawning did not differ statistically between the two treatments (P = 0.08). 
Pre-treatment prevalence also did not differ statistically between groups (P = 0.32). 
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II.4.4 Accelerometer  
II.4.4.1 Motor activity 
 Figure 6 displays an example of raw data of activity counts in a 60 minute period 
for one test subject.  Results show there was no significant effect of treatment (0.2 mg/kg 
dextroamphetamine) with all sequences confounded (P = 0.52). The accelerometer counts 
for pre-treatment placebo (116.52 ± 120) and medicated (97.75 ± 54.73) groups were 
higher than the post-treatment placebo (62.30 ± 54.39) and medicated (45.70 ± 41.48) 
groups (Figure 7). Baseline values predicted post-treatment values significantly (P = 
0.0001) but they were not affected by sequence (P = 0.09) and so post-treatment values 
needed to be corrected for baseline values. 
 
II.4.4.2 Comparison between the accelerometer and observational motor activity data 
Results show there was a strong relationship between the accelerometer counts 
measured and the observational percentage time spent “mobile’ (“exploration” + 
“locomotion”) (P < 0.0001) (Figure 8). There was an inverse relationship between time 
spent “immobile” and activity count’s (P < 0.0001). 
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II.5 Discussion 
This study demonstrates that Beagle dogs receiving one oral dose of 0.2 mg/kg of 
dextroamphetamine do not show significant changes in body temperature, specific 
behaviors such as “lip-licking”, “panting”, “yawning”, and  motor activity.  The marginal 
increase in temperature of medicated dogs in Sequence 2 (medication; placebo), may be 
due to chance, or may in fact be representative of changes seen in other studies 17,18 where 
normal Beagle dogs had increased mean body temperature 0.5 - 1 hour after administering 
0.75 - 2.0 mg/kg of oral dextroamphetamine. 
 
“Panting” frequency in both post-treatment groups was reduced from 66.7% to 
16.7%. This result may simply display habituation effect. 
 
The results do show that although as a group the medicated dogs presented a 
significantly lower heart rate than the placebo group, individual dogs showed variability in 
heart rate. This variability would suggest that a low dose dextroamphetamine test resulting 
in decreased heart rate in Beagles may in fact not identify truly hyperkinetic dogs. It is also 
possible that some of these dogs (Beagles) are true “responders” to amphetamines. Dogs 
may be considered “responders” or “non-responders” to treatment with amphetamines, 
based on early studies using the Telomian-Beagle hybrid dog as an endogenous model of 
Hyperkinetic Syndrome in children.18, 19 These studies described behavioral changes at high 
doses of dextroamphetamine in both control and hybrid dogs. These Telominan-Beagle 
hybrid dogs had been shown to exhibit hyperactivity, impulsiveness and impaired learning. 
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When Corson and Corson20 attempted to train the Telomian-Beagle dogs in a Pavlovian 
stand either with positive or negative reinforcement they found variability in response to 
treatment with dextroamphetamine. At doses of 1.2 - 2.0 mg/kg, the hybrid dogs could be 
differentiated into two groups: “responders” and “non-responders”. The “responder” dogs 
displayed marked improvement after administration of dextroamphetamine in the inhibitory 
field test (a modified sit-stay test) and did not have the hyperthermic or stereotypic 
responses of the control Beagle dogs and “non-responder” hybrid dogs.18,20 Further studies 
on these hybrid dogs showed that there may be neurochemical differences between the 
“responders” and “non-responders”. “Non-responder” dogs were found to have defects in 
dopamine receptors at the post-synaptic level and so were not sensitive to the action of 
amphetamine. In the case of the “responders” the dopamine defect was at the pre-synaptic 
level and so they were responsive to amphetamines.18 These studies show that HS may be 
determined on a polygenic basis and that each individual dog may have different 
neurochemical defects that lead to the expression of the same behavioral signs.18,19,21 
 
The response of dogs in our study to a low oral dose of dextroamphetamine may 
have been influenced by multiple factors such as the individual dogs’ neurochemistry, the 
dose of stimulant given, as well as the amount of time allotted to evaluate drug effect. In 
previous studies18, increased body temperature and stereotypic behaviors of control Beagles 
at 2.0 mg/kg (high dose) were notable and peaked at 0.5 - 1 hour and 6 - 6.5 hours 
respectively after administration. Stereotypic behaviors in this study were described as 
those consisting of repetitive walking forward and backward, jerking movements such as 
head wagging, and circling. These Beagles had peak plasma amphetamine levels at 1.5 
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hours post administration.21 It is hypothesized by several authors2,6,16 that dogs that do not 
suffer from HS will exhibit typical autonomic arousal such as increased arousal and 
activity, increased heart and respiratory rates and possibly hyperthermia, tremors and 
anorexia when challenged with amphetamines. 
 
Dextroamphetamine at oral doses of 1 - 2 mg/kg could induce various stereotyped 
behaviors, including head bobbing, circling, pacing and sniffing.2,17  A recent study by 
Tontodonati et al.17 discovered that Beagle dogs receiving low oral doses of 
dextroamphetamine (between 0.25 – 0.75 mg/kg) did not have significant change in their 
heart rates 1 – 20 hours after treatment. However at higher doses of 1.5 mg/kg the Beagle 
dogs displayed an increase in heart rate. The Tontodonati et al17 study contradicts our 
findings, since a lower dose of 0.2 mg/kg did cause a significant reduction in heart rate in 
our study Beagle dogs. Frequency of heart rate monitoring, method of monitoring and 
length of monitoring may account in part for differences between these studies. 
Tontodonati et al17 monitored heart rate on a continuous basis using an implanted ECG 
electrode telemetry device whereas our study used a Polar® heart rate monitor. 
 
In a practical sense, it is very difficult to study behavior in dogs in their natural 
home environment. It may be seen as intrusive and very time-consuming. As reported in 
other studies13,14 the use of the accelerometer in this study was shown to be a reliable tool 
for measuring motor activity in the dog. Nearly 83% of the variation in the activity counts 
could be predicted using observed time spent “mobile”. When comparing the activity 
counts with time spent “unknown” (“unknown = “other” and “non-visible”) there was a 
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positive relationship between the measures. Only 21% of the variation in the accelerometer 
counts could be predicted using “unknown” values which indicate that certain body 
movements may or may not be recorded as activity counts depending on the 
accelerometers’ minimal threshold setting. Yamada and Tokuriki14 found that at lower 
thresholds, such as 0.02G, more subtle movements (head movements) were recorded by the 
accelerometer. The accelerometers used in veterinary research are presently small in size 
and the collar mounted location has been found to be the most reliable location on the 
dog.13 Other objective methods for measuring motor activity such as grid-line tests 22,23 and 
pedometers have been used.24 The reliability of these measures however is questionable. In 
a study by Chan et al.24 pedometers and owner-reported activity were correlated (r = 0.305) 
but it was also noted that pedometer accuracy differed with both size and gait of the dog. 
 
Both in human and animal studies, the accelerometer does not provide any 
information regarding co-ordination of movements, the purposefulness, appropriateness or 
the goal directedness of the activity it is recording. Regardless of its shortcomings, 
objective measures such as the accelerometer can be used as an adjunct to conventional 
subjective diagnostic tools including rating scales and observational studies.  
 
Recently, a 13 item rating scale questionnaire was developed for dog owners to 
measure attention deficit and activity-impulsivity in their dogs and its validity and 
reliability were measured.25 This questionnaire was primarily developed as a “tool for 
describing the typical responses of pet dogs to common stimuli in their natural 
environment”. Although the study indicates that this questionnaire is both valid and 
  
50
reliable, it does not however test for different raters other than the owners. As in human 
studies26, there may be poor concordance between raters and this should be investigated 
further with this specific canine rating scale. The possible use of this type of rating scale in 
conjunction with amphetamine response tests could perhaps allow for a more 
comprehensive evaluation and diagnosis of HS in dogs. 
 
II. 6 Conclusion 
Based on the results in this study, the response to dextroamphetamine challenge in a 
dog is not likely to be a diagnostic tool for hyperkinesis. It is also possible that non-HS 
dogs may respond physiologically to amphetamines in a similar way as truly HS dogs 
respond. If this were in fact true, the diagnostic criteria used in the amphetamine challenge 
response test presently described in behavior reference texts and publications would not be 
valid for diagnosis of HS. If a dog responds paradoxically to amphetamines, it may in fact, 
simply respond to treatment with amphetamines (i.e. be a responder). 
 
Beagle dogs in this study did not display any significant changes in body 
temperature, motor activity and certain specific behaviors such as “lip-licking”, “panting” 
and “yawning” within 90 minutes of receiving an oral dose of 0.2 mg/kg of 
dextroamphetamine. The heart rate of the studied Beagle dogs was significantly reduced 
with treatment as is seen in a paradoxical response indicating that a low dose oral 
dextroamphetamine challenge test may in fact not identify truly hyperkinetic dogs.  This 
test would simply reveal “responders” to this drug. 
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The accelerometer is a reliable tool to measure motor activity in dogs. 
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II. 8 Table Legend 
Table I. Behavioral categories and specific behaviors for observational video 
analysis 
Behavioral 
Categories* 
Behaviors# Description 
Activity Immobile Immobile sitting down, lying down, immobile standing, or immobile 
stand-2-pelvic (standing on 2 pelvic limbs) 
 Locomotion Walking or running around without exploring the environment (pacing) 
 Exploration Any activity directed toward physical aspects of the environment, 
including sniffing, close visual inspection and gentle oral examination 
such as licking 
 Not-Visible  
 Other Any behavior not previously described within this category including 
shaking and scratching body parts. 
Facial Panting Rapid and shallow breathing with mouth open 
 Not-Panting Normal breathing, mouth closed 
 Yawning 
(Event) 
Yawning 
 Lip-licking 
(Event) 
Tongue out and licking lips, nose or face. Tongue seen. 
* The behavioral categories are not mutually exclusive. 
# All behaviors are state (duration) variables except for lip licking and yawning in the category of facial. All 
behaviors within each category are mutually exclusive with the exception of behaviors recorded as event. 
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II. 9 Figure Legend 
Figure 1: Placebo controlled cross-over study design. 
Diagram of study design displaying Sequence 1 (placebo; medicated) and Sequence 2 
(medicated; placebo) in a cross-over design. 
 
Figure 2: Photograph of dog wearing neck-mounted Actical® accelerometer. 
Photograph of dog wearing an activity monitor used to detect body movements in dogs 
This unit contains an omni-directional accelerometer which is sensitive to movement in all 
directions at a minimal force of 0.1G. It is most sensitive to movement in the direction 
parallel with the longest dimension of the accelerometer case (horizontal in the case of the 
dog carrying it on his neck). Voltage generated by the sensor is amplified and filtered by 
analog circuitry and then converted within a microprocessor to create a digital value. 
Photograph thanks to Bio-Lynx Scientific Equipment Inc., Montréal, Québec, Canada. 
 
Figure 3: Photograph of study dog wearing a chest mounted Polar® Heart Monitor. 
Heart beats per minute were collected every 5 seconds over the duration of the study 
periods. The results were downloaded to a computer after each 1.5 hour testing period. 
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Figure 4: Effect of treatment (0.2 mg/kg dextroamphetamine) and placebo on mean 
body temperature in both sequences as measured in degrees Celsius. 
This figure displays the effect of 0.2 mg/kg oral dextroamphetamine on the Beagle dog’s 
rectal body temperature as measured in degree Celsius°. The 2 Sequences on the y axis 
represent: Sequence 1 (placebo; medicated) and Sequence 2 (medicated; placebo). 
 
Figure 5: Box plot of the effect of 0.2 mg/kg of oral dextroamphetamine on heart 
rate. 
Lines within each box show the median and the box extends from the 25th and 75th 
percentile. Bards extend from the boxes to reach 1.5 times the interquartile range and dots 
are data points beyond this range. 
 
Figure 6: Example of 60 minutes of activity counts collected using the Actical® 
accelerometer. 
Example of raw activity scores from one subject during a one hour period within the study. 
The accelerometer unit was selected as 15 seconds. Every 15 seconds the voltage generated 
within the accelerometer is compressed and converted into an integer and reported as an 
activity count. The data was downloaded to a computer by placing the Actical® unit into a 
telemetric reader after each study period. 
 
Figure 7: Average collar mounted activity counts / 15 seconds 
  
58
Average collar mounted accelerometer counts / 15 seconds in all 4 groups including pre-
treatment recorded activity. Treatment consisted of placebo or medication (0.2 mg/kg oral 
dextroamphetamine). 
 
Figure 8: Correlation between time observational time spent “mobile” and collar 
mounted Actical® counts. 
Correlation between the video observational time spent “mobile” (time spent “exploring” 
and time spent in “locomotion”) and the collar mounted accelerometer activity counts. 
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* Days 10-14: Allowed time for adequate washout period. 
** Medicated: Dogs receiving 0.2 mg/kg oral dextroamphetamine. 
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Figure 2. Photograph of dog wearing neck-mounted Actical® 
accelerometer.  
 
 
Figure 3: Photograph of study dog wearing chest mounted Polar® Heart 
Monitor. 
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Figure 4: Dogs receiving 0.2 mg/kg of oral dextroamphetamine had no effect on mean body 
temperature within 90 minutes of treatment with all sequences confounded (p = 0.18). In 
Sequence 1 (placebo; medication) there was no significant effect of treatment (p = 0.39). In 
Sequence 2 (medication; placebo) there was a 0.13°C increase in mean body temperature in 
the medicated dogs (p = 0.016). 
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Figure 5. Box plot of the effect of 0.2 mg/kg oral dextroamphetamine on 
heart rate 
 
Figure 5: Box plot of the effect of 0.2 mg/kg of oral dextroamphetamine on heart rate. 
Lines within each box show the median and the box extends from the 25th and 75th 
percentile. Bards extend from the boxes to reach 1.5times the interquartile range and dots 
are data points beyond this range. 
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Figure 7:  Average collar mounted 
accelerometer counts / 15 seconds
116.95
62.29
97.74
45.70
0
20
40
60
80
100
120
140
Pre-treatment
Placebo
Post-treatment
Placebo
Pre-treatment
Medicated
Post-treatment
Medicated
A
ve
ra
ge
  a
cc
el
er
om
et
er
 c
ou
nt
/1
5 
se
c 
 
 
 
Figure 7: Treatment consisted of placebo or medicated (0.2 mg/kg dextroamphetamine).  
When post-treatment values were adjusted for baseline pre-treatment values, there was no 
significant difference between placebo and medicated groups (p = 0.52) with all sequences 
confounded. 
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Chapter III Discussion and Conclusion 
III.1 General Overview 
 Veterinary clinical practitioners currently lack adequate diagnostic criteria and 
techniques for evaluating Hyperactivity or Hyperkinesis Syndrome (HS) in domestic dogs. 
Evidence-based tools for the identification and diagnosis of HS in practice are badly 
needed. It is the author’s belief that proper diagnosis and treatment of dogs that truly suffer 
from HS would lead to fewer cases of euthanasia due to behavioural problems and an 
improved quality of life for those dogs and their caregivers. 
The key research question which this thesis attempts to answer is: How do we 
identify dogs as suffering from HS if we do not know what constitutes a ‘normal’ activity 
level in the dog population? The current diagnostic practice for this syndrome uses a single 
response test which could easily lead to misdiagnosis. 
The dextroamphetamine response test described in Chapter I and originally 
developed in the 1970s was designed using a very specific group of dogs:  the Telomian-
Beagle hybrid dogs, which displayed certain clinical signs of “hyperkinesis” (Corson & 
Corson 1976). The test was then further investigated by Campbell (1973) using case-based 
trials of domestic owned dogs who appeared to display behaviours congruent with 
“hyperkinesis” (as defined at that time, see section I.1.5).  The definitions and behavioural 
criteria being used in current clinical practice to identify dogs possibly suffering from HS 
vary amongst authors, leading to great debate in the field of veterinary behavioural 
medicine. Even the clinician’s selection of which dogs should undergo the diagnostic 
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amphetamine response test is variable. We suggest that a primary clinical interpretation of 
dogs presenting with abnormal activity levels and/or inattention is not possible, given the 
significant lack of baseline data on ‘normal’ dog activity and attention. 
In humans, the use of amphetamines to treat children and adults with Attention-
Deficit Hyperactivity Disorder (ADHD) was a secondary development for treatment and 
amphetamines are not used as a primary method of diagnosis as they are in the veterinary 
literature. People suffering from ADHD must first be diagnosed with the disorder based on 
thorough diagnostic criteria such as that seen in the Conners Teacher Rating Scale (see 
I.1.3) (Annex I). Rating scales have only very recently been investigated in the veterinary 
literature and are not currently being used as a diagnostic tool for HS (Vas et al. 2007). 
In section III.2, the clinical implication of the research study conducted will be discussed 
while in section III.3 and III.4, the limitations of the study and future research possibilities 
will be reviewed. 
III.2 Clinical Implications  
HS is defined as a syndrome. A syndrome is generally classified as a group of 
symptoms that collectively indicate or characterize a disease, psychological disorder, or 
other abnormal condition (American Psychiatric Association 1994). HS can be considered a 
syndrome because it does not have one compelling clinical sign associated with it but 
instead presents a group of symptoms. At present, however, diagnosis of HS in dogs is 
based mainly on the use of a single objective diagnostic response test on dogs that display 
some or all of a highly variable list of clinical behavioural signs. 
  
68
In human medicine, hyperactivity is a central feature of ADHD (Attention-deficit 
Hyperactivity Disorder), and is usually defined as excessive or developmentally 
inappropriate levels of motor activity. The diagnostic criteria of ADHD have evolved in the 
past 30 years, as the lifestyles of children have changed dramatically requiring them to 
spend more time in classrooms and being inactive yet attentive for long periods of time. 
With an estimated 3-5% of all children in North America suffering from ADHD (Barkley 
1996) there has been a great deal of research undertaken to understand the factors involved 
in this disorder, their proper diagnosis and treatment. There is now thus some question 
whether this disorder existed 100 years ago, when children in North America and the 
western world, spent most of their time doing physical activity rather than sitting in 
classrooms. 
In human medicine, in contrast to veterinary medicine, response to amphetamines is 
not used as a diagnostic test in ADHD in children or adults. A double-blind cross-over 
study done in by Zhan et al. (1980) discovered that dextroamphetamine affected both 
normal and hyperactive boys in a similar way. Both groups of children showed on average 
reduced motor activity and impulsivity, improved attention and reduced heart rate prior to a 
reaction time task test. 
Additionally, there remains much controversy over the possible over-diagnosis and 
over-treatment of ADHD with amphetamines among the general public and medical 
profession. The study by Zhan et al. (1980) in combination with clinical interpretations in 
the field, have led investigators and clinicians to question the abundant use of stimulants in 
the treatment of children with ADHD as there is likely a subgroup of children who truly do 
not have ADHD but still respond paradoxically to stimulants. 
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In the present study, similar results to the human clinical response were found:  
overall, Beagle dogs that were not displaying behavioural signs of HS responded in a 
paradoxical fashion with respect to heart rate. As an example, Beagle dog #9 was found to 
have a baseline average heart rate of 113 bpm. After receiving 0.2 mg/kg 
dextroamphetamine, the average heart rate during the following 90 minutes for this dog 
decreased to 77 bpm (a reduction of 33 percent). If this particular dog had been presented 
for behavioural evaluation in a veterinary clinic and a clinician followed the recommended 
amphetamine response test described by various authors (see section I.1.5), a misdiagnosis 
of canine HS could easily have been made. 
In veterinary practice it would be unlikely that a clinician would attempt an 
amphetamine-response test in a dog that is not displaying any signs of HS behaviourally. 
Diagnostic behavioural criteria for HS in dogs are however vague and inconsistent in the 
literature. The combination of poor behavioural criteria and a diagnostic test that has not 
been based on scientific evidence may lead to dogs being inappropriately labelled as either 
“normal” or HS. It is possible that, as with some children, dogs may display certain 
‘paradoxical’ changes when given amphetamines, even if behaviourally non-HS. 
The use of objective measurements in combination with well designed rating scales 
may allow veterinary investigators the added advantage of further defining canine 
hyperactivity in terms of quantity and pattern rather than defining it categorically through 
an amphetamine response test. Currently available human diagnostic tools include rating 
scales (parent and/or teacher) (Conners 1969, Annex I) as well as other psychometric 
evaluations and in some cases the use of solid-state actigraphs, and pedometers to measure 
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the activity level of the person. Given that ADHD is among the most frequently diagnosed 
child psychiatric disorder (Barkley 1996) it is not surprising that human medical 
professionals are working towards establishing more objective methods of diagnosis. 
There are currently a number of behavioural methods available to veterinarians. 
Until recently, most veterinary behaviourists used the published questionnaires and 
temperament tests of Goddard & Beilharz (1984), Hennessy et al. (2001) and Hsu & Serpell 
(2003).  Categories and labels such as “Activity” (Goddard & Beilharz 1984), “Locomotor 
activity” (Hennessy et al. 2001) and “Excitability and Trainability” (Hsu & Serpell 2003) 
were used in these questionnaires and temperament tests. These subjective clinical 
evaluations were not well validated and most studies did not address validity issues. 
In comparison, the new Vas et al. (2007) 13-item rating scale questionnaire was 
primarily developed as a “tool for describing the typical responses of pet dogs to common 
stimuli in their natural environment”. With further investigation and validation, it is the 
author’s hope that clinicians and behaviourists will be able to use this scale for improved 
diagnostic capabilities for HS and other behavioural problems, in preference to unreliable 
and potentially misleading amphetamine response tests. 
Using remote devices such as the accelerometer may also reduce a researcher’s time 
and energy significantly when studying motor activity in the dog. It allows researchers to 
use a quantifiable method to assess motor activity in the dog in many different 
environmental settings (home, office, kennel, etc). The accelerometers used in veterinary 
research are presently small in size, lightweight and in some cases, already collar mounted 
(as was the device used in this study). Using diagnostic criteria such as objective measures 
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of motor activity and validated rating scales in addition to response-tests, may improve the 
diagnostic capabilities of clinicians for HS. 
In conclusion, the findings of this study suggest there is good reason to question the 
use of the diagnostic HS test in clinical practice. At 0.2 mg/kg, oral dextroamphetamine 
may cause Beagle dogs to display a paradoxical reduction in heart rate potentially leading 
to misdiagnosis of HS. It is clear that the definition of HS is highly variable and 
controversial even amongst veterinary behaviourists. This syndrome is clinically ill-defined 
and further investigation is needed. Validating current or new rating scales may assist in 
defining this syndrome. Studies using rating scales will allow for larger representative 
groups of dogs to be evaluated, improving the strength of these studies. Without baseline 
studies of motor activity and impulsive/attentive tendencies in the pet dog population, an 
accurate diagnosis of HS is impossible. In other words, a diagnosis of “abnormal” 
behaviour is suspect if we have not first defined “normal” behaviour. 
Without a true definition and clear diagnostic clinical signs, veterinary behaviourists 
may simply refer to dogs that respond paradoxically to amphetamines as “amphetamine 
responsive”. Instead of this test being a diagnostic test, it is in reality more of a treatment 
trial. Are the dogs that respond paradoxically to dextroamphetamine truly HS?  From our 
present study, we can extrapolate that some Beagle dogs may respond paradoxically even 
when not behaviourally HS (using the current behavioural clinical signs associated with HS 
in the literature). 
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III.3 Limitations of the Study  
III.3.1 Study Design and Methodology 
III.3.1.1. Dose of Dextroamphetamine and Length of Monitoring 
 The responses resulting from the low doses of 0.2 mg/kg dextroamphetamine on the 
study Beagle dogs may have been influenced by the dose of stimulant given, as well as the 
amount of time allotted to evaluate effect. It is possible that had higher doses of 
dextroamphetamine been used very different effects of treatment on the study dogs may 
have been seen. Behavioural effects of dextroamphetamine in humans are increased by 
larger doses. Over the course of a given dose, however, there is a divergence between such 
behavioural effects and drug concentration in the blood (Angrist et al. 1987). In particular, 
behavioural effects peak before maximal blood levels are reached, and decline as blood 
levels remain stable or even continue to increase. 
Results could also have been influenced by length of time the test dogs were 
monitored and data collected. The decision to take measurements up to 90 minutes after the 
dogs received medication was based on the previously described amphetamine response 
test (see section I.1.5). As mentioned in the introduction of this thesis, the original study 
design included a dosing regime of both 0.2 mg/kg and one of 1.3 mg/kg 
dextroamphetamine. The first dog to receive the higher dose of 1.3 mg/kg displayed 
stereotypic behaviours 3.5 hours after receiving the oral dose (personal communication, Dr 
Diane Frank). For reasons of animal welfare, the higher dose regimen was discontinued. 
Although this observation was of a single dog, prior publications suggest that higher doses 
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such as 0.75 - 2.5 mg/kg are likely to cause significant neurobehavioral effects including 
stereotypies and vocalizations (Bareggi et al. 1978; Tontodonati et al. 2007). 
In our study the marginal increase in body temperature of medicated dogs in 
Sequence 2 (medication; placebo) may have been due to chance, or may in fact be 
representative of changes seen in other studies. Other studies have used higher doses of 
dextroamphetamine and monitored the changes in body temperature over a greater length of 
time. Bareggi et al. (1979a) suggested that there was a significant increase in mean body 
temperature 0.5 – 1 hr after administering 2.0 mg/kg of dextroamphetamine. Tontodonati et 
al. (2007), noted an increase in body temperature (up to 1.2 and 2.5 °C) when dosing dogs 
at 0.75 and 1.5 mg/kg dextroamphetamine respectively. The effect of these higher doses 
was observed between 0.5 and 10 hr after dosing and peaked at 2 hr post-dose (Tontodonati 
et al. 2007). Prior publications suggest that there is a dose-dependent effect of 
dextroamphetamine on body temperature and that as the dose of dextroamphetamine 
administered increases, so too may body temperature (Bareggi et al. 1979; Tontodonati et 
al. 2007). Our study did not investigate more than one dose of dextroamphatemine, so we 
were unable to test a possible dose dependent effect. 
Previous studies also suggest that there is a dose dependent effect on heart rate.  
Results from Tontodonati et al. (2007), suggested that heart rates may increase significantly 
at doses of 1.5 mg/kg, between 1 - 20 hrs after oral dosing and that lower doses such as 
0.25 and 0.75 mg/kg will not cause a significant change in heart rate. If the heart rate 
increases significantly when giving an amphetamine, it suggests a direct and positive 
chronotropic effect on the cardiovascular system of that animal. Contrary to Tontodonati’s 
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study (using 0.25 mg/kg oral dextroamphetamine), the present study displayed a significant 
effect of a low dose of dextroamphatemine (0.2 mg/kg) on heart rate in studied Beagle 
dogs. 
With respect to changes in motor activity as a result of our tested low-dose of 
dextroamphetamine, there was no change in motor activity (video-recorded or by 
accelerometer) in the Beagle dogs. These results are similar to findings of Tontodonati et al. 
(2007) which suggested that Beagle dogs receiving doses of 0.25 mg/kg did not have any 
significant change in locomotion as measured by an implanted telemetry device or with 
observational video recordings. At higher doses of 0.75 mg/kg and 1.5 mg/kg, the 
Tontodonati et al. (2007) study showed that dogs would have an increase in locomotion 
between 2 to 5 hours post dosing. It is important to note that although the Tontodonati et al. 
(2007) study used a very small sample size (4 dogs) it was, to the author’s knowledge, the 
first study performed that objectively evaluated the effect of dextroamphetamine on motor 
activity in the research Beagle. 
III.3.1.2 Observational Descriptions and Specific Behaviours  
In this study, specific behaviours were selected for observation based on their 
possible use as indicators of stress or anxiety. “Lip-licking”, “yawning” or “panting” are 
three specific behaviours studied in this trial. However it is recognized that stress and 
anxiety are not the exclusive emotional or physiological factor behind the frequency or 
occurrence of dogs lip-licking, yawning or panting. For example, stress, anxiety, ambient 
temperature, and activity may all lead to an increase in frequency of panting. Stress, nausea 
and anxiety may all lead to lip-licking (Beerda et al. 1998). None of these behaviours has 
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been previously studied in dogs receiving dextroamphetamine or other amphetamines and 
so it is difficult to comment on the likelihood of changes in these behaviours (frequency or 
duration) when the dogs are subjected to dextroamphetamine. It is possible that if dogs at 
higher doses of dextroamphatemine tended to show more excitement and 
vocalizations/stereotypies (Bareggi et al. 1978; Tontodonati et al. 2007), then we could 
extrapolate that these dogs would display an increase in frequency and/or duration of stress 
induced behaviours such as panting and yawning. Panting could also be increased in dogs 
with greater environmental and body temperatures, a factor that was not investigated for 
effect. 
The behavioural categories in this study were defined prior to any observations of 
the study dogs. The stated variables of locomotion and exploration were found to be 
difficult to differentiate at times during video observation. For example, when the subject 
dog’s head was facing away from the camera, it was unclear as to whether he/she was goal 
directed (exploration) or not. For this reason and due to low frequency of the locomotion 
behaviour, both “locomotion” and “exploration” were combined to form time spent 
“mobile” for the purposes of analysis of activity data. 
III.3.1.3 Beagles as Study Subjects and the Possible Influence of Heritability and 
Genetics on HS and ADHD 
The present study used research Beagle dogs to help control for variations between 
breeds and other environmental factors. This homogeneity of subjects allowed for ease of 
data collection and analysis. Using this type of study subject group, however, made it 
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difficult to compare with other studies and to extrapolate results found in the general dog 
population of owned dogs. 
This homogeneity of study subjects is found in many other comparative studies 
investigating the effect of amphetamines on dogs. Beagle dogs raised for research purposes 
may not however be representative of the owned domestic dog population both 
behaviourally and physiologically. Using a cohort of subjects from a variety of breeds, 
ages, and sexes of domestic owned dogs would have provided the study with a better 
representation of the pet dog population seen in clinical practice. This type of clinical study 
however, would be difficult to repeat and validate given the gene-environment interaction 
seen in the pet population described recently (Hejjas et al. 2007).  Using pet dogs for 
pharmacological research, especially with potentially harmful medications such as 
dextroamphetamine, is ethically questionable and does not support animal welfare. Using 
Beagles allowed us to control for many environmental factors and complete an early 
investigation on the use of dextroamphetamine in diagnostic testing of HS. 
  A recent publication by Hejjas et al. (2007) studied the association between the 
dopamine D4 receptor gene (DRD4) polymorphism and activity-impulsivity scores (using 
the 13-item rating scale mentioned in section I.1.3.1 ) in a single breed population (200 
German Shepherd dogs). In humans, DRD4 variable number of tandem repeats (VNTR) is 
thought to be related to ADHD (Faraone et al. 2005). In dogs, a similar repeat 
polymorphism in DRD4 gene has been suggested by Niimi et al. (1999). 
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The question as to whether behaviour traits such as aggression, excitability, and 
activity are heritable and/or due to variations in the DRD4 gene has been the focus of recent 
canine studies (Niimi et al. 1999; Hejjas et al. 2007). In children, the heritability of ADHD 
has been estimated to be as high as 80% (Thapar et al. 2000). To the author’s knowledge, 
there are no studies on the heritability of HS in dogs. Given the veterinarian’s perceived 
rarity of HS in the pet dog population and the variability of criteria used to diagnose this 
syndrome, the lack of research on this subject is not surprising. 
Results from Hejjas et al. (2007), found that DRD4 VNTR polymorphism was 
associated with the activity-impulsivity score of an environmentally homogeneous group of 
police dogs. The same investigation was performed using a population of pet German 
Shepherd’s and this genetic association with activity–impulsivity scores was not found 
(Hejjas et al. 2007). It is clear from this study that there is an important interaction between 
genetics and environment when investigating this DRD4 polymorphism. The 
environmental interactions (nutrition, housing, relationships, etc), may affect the 
phenotypic expression of dogs with this polymorphism. This polymorphism in a German 
Shepherd dog is not necessarily predictive of an elevated activity-impulsivity score (and 
perhaps dogs suffering from HS). Future studies investigating other breeds and factoring 
for specific environmental factors are needed. 
Age and sex of subjects in the present study were not factored into the analysis. An 
equal male-to-female ratio was used in the study and all dogs were within 13 - 20 months 
of age. To the author’s knowledge, there has been no objective research performed 
investigating age or sex in dogs with respect to incidence of HS or of the effects of 
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amphetamines on these differing ages or sexes. Other studies such as those done by 
Tontodonati et al. (2007) and Bareggi et al. (1979a) used very small cohorts of subjects and 
did not do factor analysis with age or sex. In humans, ADHD is seen more commonly in 
boys than it is in girls (Barkley 1996). Vas et al. (2007) found that juvenile dogs (10 - 24 
months of age) qualified as being more inattentive than adult dogs using an owner rated 13-
item scale. This same study found no significant difference between inattention in male and 
females. Male juvenile dogs however were found to have a tendency (but not significant) to 
have higher “activity-impulsivity” scores. 
III.3.1.4 Measuring Activity: Observational versus the Accelerometer  
The use of the accelerometer in this study, as in others (Yamada & Tokuriki 2000; 
Hansen et al. 2007), suggests that it is a reliable tool for measuring motor activity in the 
dog. Observational activity studies are both intrusive and very time-consuming and 
laborious. Other objective methods for measuring motor activity such as grid-line tests 
(Wilson & Sundgren 1998; Hennessy et al. 2001) and pedometers have been used (Chan et 
al. 2005). For instance pedometers and owner-reported activity were correlated at (r = 
0.305) in a study by C.B. Chan et al. (2005). It was however found that pedometer accuracy 
differs with both size of the dog and the dog’s gait (Chan et al. 2005). Hansen et al. (2007) 
demonstrated that the accelerometer correlates positively with video-graphic measurements 
of movement and mobility in dogs with a weight ranging between 18kg - 28kg. 
 Despite these advantages, the accelerometer (in both human and animal studies) 
does not provide any information regarding the level of co-ordination of movements, their 
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purposefulness or appropriateness, or the goal directedness of the activity recorded, which 
may be important information for the researcher. In the present study, there were some 
difficulties with proper categorization of “locomotion” and “exploration”. This could have 
been improved upon if the observer understood the goal directedness of the studied activity. 
The accelerometer, for instance, would not have assisted in quantifying these types of 
behaviours or stereotypies as they would appear simply as an increase in motor activity. 
Underlying emotional or behavioural response is also not measurable by the accelerometer. 
 
III.4 Future Studies  
It is evident from the above discussion that there is a need for more research in the 
field of canine motor activity, inattention and impulsivity. Can we objectively assess 
baseline motor activity, inattention and impulsivity in dogs? What is the normal amount of 
motor activity in the pet dog population? What is the normal attention span of a dog? Do 
factors such as breed, size of dog, age, environment, or lifestyle or a combination of all 
these factors affect motor activity and attention? Large cohort, multi-factor, multi-
disciplinary studies are needed, such as those seen in human studies. 
Accelerometer motor activity studies on the owned pet dog population in the home 
and hospital environment would give veterinarians and the public some baseline data on the 
“normal” motor activity of pet dogs.  If these proposed studies were used in conjunction 
with the newly published 13-item activity and impulsivity rating scale in Vas et al. (2007), 
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it may allow for the development of reliable and validated diagnostic criteria for dogs 
suffering from true HS. 
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III.5 Overall Conclusion 
As the new specialty of veterinary behavioural medicine grows in North America, 
so should the advancement and promotion of evidence-based behavioural medicine.  
Currently dogs that are presented to veterinary clinicians with suspected Hyperactivity or 
Hyperkinesis Syndrome are evaluated against a list of clinical signs that are considered to 
be typical criteria for this syndrome in dogs. These clinical signs, as discussed section II, 
are varied, inconsistent and controversial. There is little evidence to date as to the 
diagnostic validity of these clinical signs and whether certain factors, such as age, breed, 
sex, genetics and environment play a role. Moreover, if a dog displays certain or all of these 
clinical signs, then the clinician may perform a further diagnostic test using an 
amphetamine-response regimen as recommended in most veterinary behavioural texts and 
manuals. 
The primary objective of this thesis was to examine the reliability of the 
amphetamine-response test. The rationale behind this test is that dogs responding 
“typically” to amphetamines will show either an increase or no change in physiological 
responses such as heart rate, respiratory rate and motor activity. Conversely, a decrease of 
these parameters suggests a paradoxical response in the aforementioned markers, indicating 
that the dog suffered from HS. 
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In this study, when the effects of 0.2 mg/kg oral dextroamphetamine were measured 
on behaviourally non-HS Beagle dogs, we expected to see either no change or a stimulant 
effect as described above. The present study suggests however that this assumption may not 
be true in all cases or for all the markers as the test dogs showed a significant reduction in 
heart rate with this low-dose of oral dextroamphetamine. These results are contradictory to 
other studies, which have suggested that at such low-doses of dextroamphetamine, Beagle 
dogs should not show any significant change in heart rate. 
The veterinary literature assumes that dogs which respond paradoxically to 
dextroamphetamines are in fact, suffering from HS. However the dogs in this study 
displayed no clinical signs of HS despite a paradoxical reduction in heart rate. This 
unexpected result is in fact similar to that found in human studies, where a number of 
children who are not clinically ADHD respond paradoxically to amphetamines, suggesting 
that this test may not a reliable indicator of HS in dogs. 
In conclusion, it is recommended that the amphetamine response test for HS be used 
with caution and as only one of many diagnostic tools for the veterinarian. Alternatively, 
the amphetamine response test could be used clinically as a treatment trial to determine 
appropriate drug therapy for behaviourally hyperactive, hyper-stimulated, or over-active 
dogs. In this case, researchers will need to quantifiably measure what is “normal” motor 
activity, and also what constitutes inattention and impulsivity for the pet dog, as there is 
presently no normative data against which to measure any “abnormal” activity observed in 
a clinical or laboratory settings. 
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In time, the newly published 13-item activity and impulsivity rating scale in 
conjunction with other more objective tools to measure activity in the dog (such as those 
used in this study) may provide the necessary information needed for the development of 
reliable and validated criteria for diagnosing HS. 
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Annex I 
Subsection IV of the Conners’ Teacher Rating Scale – Revised (S) 
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